IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)

Odabas, HaticeUlas, ArifeAydin, KubraInanc, MevludeAksoy, AsudeYazilitas, DoganTurkeli, Mehmet2024-04-242024-04-2420131556-08641556-1380https://hdl.handle.net/11468/23107[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessPrognostic FactorsSurvivalNon-Small Cell Lung CancerSecond Line TreatmentIS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)Conference Object8S876S876WOS:000339624904137Q1